Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is set to take place in New York from September 9-11, 2024.
Dr. Deborah Birx, Armata's Chief Executive Officer, will deliver a corporate presentation on Wednesday, September 11, from 8:00-8:30 AM ET. This presentation offers an opportunity for investors to gain insights into Armata's innovative approach to treating difficult-to-treat bacterial infections using high-purity, pathogen-specific bacteriophage therapeutics.
Armata Pharmaceuticals (NYSE American: ARMP), una compagnia biotecnologica specializzata in terapie a base di batteriofagi per infezioni resistenti agli antibiotici, ha annunciato la sua partecipazione al 26° Congresso Annuale di Investimenti Globali H.C. Wainwright. L'evento si svolgerà a New York dal 9 all'11 settembre 2024.
Il Dr. Deborah Birx, Amministratore Delegato di Armata, presenterà una relazione aziendale mercoledì 11 settembre, dalle 8:00 alle 8:30 ET. Questa presentazione offre un'opportunità agli investitori di approfondire l'approccio innovativo di Armata nel trattamento delle infezioni batteriche difficili da trattare utilizzando terapie a base di batteriofagi specifiche per il patogeno e ad alta purezza.
Armata Pharmaceuticals (NYSE American: ARMP), una empresa de biotecnología especializada en terapias con bacteriófagos para infecciones resistentes a los antibióticos, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El evento se llevará a cabo en Nueva York del 9 al 11 de septiembre de 2024.
La Dra. Deborah Birx, Directora Ejecutiva de Armata, presentará una presentación corporativa el miércoles 11 de septiembre, de 8:00 a 8:30 AM ET. Esta presentación ofrece a los inversores la oportunidad de obtener información sobre el enfoque innovador de Armata para tratar infecciones bacterianas difíciles de tratar utilizando terapias de bacteriófagos específicas para patógenos y de alta pureza.
Armata Pharmaceuticals (NYSE American: ARMP)은 항생제에 저항성인 감염을 위한 박테리오파지 치료제에 특화된 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 열릴 예정입니다.
Armata의 CEO인 Deborah Birx 박사가 9월 11일 수요일, 오전 8시부터 8시 30분까지 ET에 기업 발표를 진행합니다. 이 발표는 투자자들이 고순도, 병원체 특이적 박테리오파지 치료제를 사용하여 치료하기 어려운 세균 감염을 치료하는 Armata의 혁신적인 접근 방식에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Armata Pharmaceuticals (NYSE American: ARMP), une entreprise biopharmaceutique spécialisée dans les thérapeutiques à base de bactériophages pour les infections résistantes aux antibiotiques, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. L'événement se déroulera à New York du 9 au 11 septembre 2024.
Dr. Deborah Birx, PDG d'Armata, fera une présentation d'entreprise le mercredi 11 septembre, de 8h00 à 8h30 ET. Cette présentation offre aux investisseurs l'occasion de découvrir l'approche innovante d'Armata pour traiter les infections bactériennes difficiles à soigner en utilisant des thérapeutiques à base de bactériophages spécifiques aux pathogènes et de haute pureté.
Armata Pharmaceuticals (NYSE American: ARMP), ein biotechnologisches Unternehmen, das sich auf Bakteriophagen-Therapeutika für antibiotikaresistente Infektionen spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York statt.
Dr. Deborah Birx, CEO von Armata, wird am Mittwoch, den 11. September, von 8:00 bis 8:30 Uhr ET eine Unternehmenspräsentation halten. Diese Präsentation bietet Investoren die Möglichkeit, Einblicke in Armatas innovativen Ansatz zur Behandlung schwer behandelbarer bakterieller Infektionen mit hochreinen, pathogen-spezifischen Bakteriophagen-Therapeutika zu gewinnen.
- None.
- None.
Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302238686.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
When is Armata Pharmaceuticals (ARMP) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Armata Pharmaceuticals (ARMP) at the H.C. Wainwright conference?
What is the focus of Armata Pharmaceuticals' (ARMP) research?
Where is the H.C. Wainwright Global Investment Conference being held in 2024?
